台灣臨床試驗主持人資料庫|TPIDB

2017-09-30 - 2022-09-30

Phase I

A Phase 1 Study of HLX06, a Fully Human Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients with Advanced Solid Tumors Refractory to Standard Therapy

Condition/Disease

Patients with Advanced Solid Tumors Refractory to Standard Therapy
Test Drug

HLX06

Participate Sites
3Sites

Terminated3Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2016-03-01 - 2026-09-30

Phase III

Condition/Disease
Test Drug

Participate Sites
4Sites

Recruiting3Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2016-06-01 - 2017-04-01

Phase II

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2017-07-01 - 2020-03-31

Phase II

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

Condition/Disease

Metastatic Triple Negative Breast Cancer
Test Drug

Olaparib (AZD2281), AZD6738 and AZD1775

Participate Sites
10Sites

Terminated9Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of General Internal Medicine

陳訓徹

Linkou Chang Gung Medical Foundation

2018-01-01 - 2020-06-30

Phase I

A PHASE 1 STUDY OF HLX10, A HUMANIZED MONOCLONAL ANTIBODY TARGETING PROGRAMMED DEATH-1 (PD-1) PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMORS

Condition/Disease

solid tumor
Test Drug

HLX10

Participate Sites
5Sites

Recruiting5Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Condition/Disease

Alzheimer's Disease
Test Drug

Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬

Kaohsiung Municipal Gangshan Hospital

未分科

2017-09-01 - 2019-10-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Condition/Disease

Hospital-acquired Bacterial Pneumonia, Ventilator-associatedBacterial Pneumonia, or Healthcare-associated BacterialPneumonia Caused by Gram-negative Pathogens
Test Drug

S-649266

Participate Sites
4Sites

Terminated4Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

李文生

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2017-11-30 - 2019-12-30

Phase II

An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Condition/Disease

Primary IgA Nephropathy
Test Drug

LNP023

Participate Sites
4Sites

Terminated4Sites

吳麥斯

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

2018-03-08 - 2021-07-04

Phase III

A PHASE 3 MULTI-CENTER, LONG-TERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB, WITH OR WITHOUT TOPICAL MEDICATIONS, ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Condition/Disease

Atopic dermatitis (AD)
Test Drug

PF-04965842

Participate Sites
9Sites

Recruiting9Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2016-08-08 - 2017-10-31

Phase III

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Condition/Disease

plaque psoriasis
Test Drug

BI655066

Participate Sites
5Sites

Terminated5Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

Search Result

List